Quarterly ResultAug 5, 2026, 07:12 AM
Orthofix Q2 Net Sales $210.9M; Net Loss $15.8M; Debt Up
AI Summary
Orthofix Medical Inc. reported mixed financial results for the second quarter and first six months of 2026. Net sales increased to $210.9 million for the quarter, and the operating loss improved. However, the net loss for the quarter widened to $15.8 million. The company also saw a significant increase in long-term debt due to drawing down a credit facility and incurred substantial costs related to arbitration claims with former executives and an accrual for the Italian Medical Device Payback.
Key Highlights
- Net sales increased to $210.9 million for Q2 2026, up from $203.1 million in Q2 2025.
- Net loss for Q2 2026 was $15.8 million, compared to a net loss of $14.1 million in Q2 2025.
- Operating loss improved to $8.1 million for Q2 2026, down from $16.0 million in Q2 2025.
- Cash and cash equivalents rose to $103.8 million as of June 30, 2026, from $82.0 million at December 31, 2025.
- Long-term debt increased to $221.6 million as of June 30, 2026, from $157.4 million at December 31, 2025.
- The company borrowed $65.0 million via the Term B Loan on January 15, 2026.
- Paid $14.8 million for an interim arbitration award to a former executive and settled two other claims for $4.25 million each.
- Accrued $11.0 million related to the Italian Medical Device Payback (IMDP).
Price Impact
More from OFIX